Clinically relevant GSK‑3β inhibitor 9‑ING‑41 is active as a single agent and in combination with other antitumor therapies in human renal cancer

Persistent ID (NDL): info:ndljp/pid/11538623

Material type: 博士論文

Author: Anraku, Tsutomu

Publisher: -

Publication date: 2020-03-23

Material Format: Digital

Capacity, size, etc.: -

Name of awarding university/degree: 新潟大学,博士(医学)

View All

Notes on use at the National Diet Library

本資料は、掲載誌(URI)等のリンク先にある学位授与機関のWebサイトやCiNii Dissertationsから、本文を自由に閲覧できる場合があります。

Notes on use

Note (General)：: Glycogen synthase kinase-3 (GSK-3), a serine/threonine kinase, is involved in a broad range of pathological　processes including cancer. GSK-3 has two ...

Search by Bookstore

Read this material in an accessible format.

View materials in accessible formats for people with print disabilities (1Type)

Search by Bookstore

Read in Disability Resources

Other Services
- テキストデータ check it on 国立国会図書館デジタルコレクション

Bibliographic Record

You can check the details of this material, its authority (keywords that refer to materials on the same subject, author's name, etc.), etc.

Digital

Material Type: 博士論文
Title: Clinically relevant GSK‑3β inhibitor 9‑ING‑41 is active as a single agent and in combination with other antitumor therapies in human renal cancer
Author/Editor: Anraku, Tsutomu
Publication Date: 2020-03-23
Publication Date (W3CDTF): 2020-03-23
Alternative Title: 9-ING-41(GSK-3阻害剤)は、腎癌に対して単剤および併用療法として有効である
Degree grantor/type: 新潟大学
Date Granted: 2020-03-23
Date Granted (W3CDTF): 2020-03-23
Dissertation Number: 甲第4697号
Degree Type: 博士(医学)
Conferring No. (Dissertation): 甲第4697号
Text Language Code: eng
Subject Heading: glycogen synthase kinase-3
renal cell carcinoma
apoptosis
cell cycle arrest
immune cells
Note (General): Glycogen synthase kinase-3 (GSK-3), a serine/threonine kinase, is involved in a broad range of pathological　processes including cancer. GSK-3 has two isoforms, GSK-3αand GSK-3β, and GSK-3β has been recognized as a therapeutic target for the development of new anticancer drugs. The present study aimed to investigate the antitumor effects of9-ING-41, which is a maleimide-based ATP-competitive small molecule GSK-3β inhibitor active in patients with advanced cancer. In renal cancer cell lines, treatment with 9-ING-41 alone induced cell cycle arrest and apoptosis, and autophagy inhibitors increased the antitumor effects of 9-ING-41 when used in combination. Treatment with 9-ING-41 potentiated the antitumor effects of targeted therapeutics and increased the cytotoxic effects of cytokine-activated immune cells on renal cancer cell lines. These results provided a compelling rationale for the inclusion of patients with renal cancer in studies of 9-ING-41, both as a single agent and in combination with current standard therapies.
International Journal of Molecular Medicine. 2020, 45(2), 315-323.
新大院博(医)甲第931号
DOI: info:doi/10.3892/ijmm.2019.4427
https://doi.org/info:doi/10.3892/ijmm.2019.4427
Persistent ID (NDL): info:ndljp/pid/11538623
https://dl.ndl.go.jp/pid/11538623
Collection: 障害者向け資料
Collection (Materials For Handicapped People:1): テキストデータ
Collection (particular): 国立国会図書館デジタルコレクション > デジタル化資料 > 博士論文
https://dl.ndl.go.jp/collections/A00014
Acquisition Basis: 博士論文（自動収集）
Date Accepted (W3CDTF): 2020-09-07T06:04:08+09:00
Date Created (W3CDTF): 2020-08-31
Format (IMT): application/pdf
Access Restrictions: 国立国会図書館内限定公開
Service for the Digitized Contents Transmission Service: 図書館・個人送信対象外
Availability of remote photoduplication service: 可
Periodical Title (URI): http://hdl.handle.net/10191/00051820
Data Provider (Database): 国立国会図書館 : 国立国会図書館デジタルコレクション
https://dl.ndl.go.jp